MarketBeat
11 Aug 2026, 00:05 UTC · 2h ago
Oncocyte Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
11 Aug 2026, 00:05 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
The FDA issued an additional information letter requesting more data and clarification on the GraftAssureDx test's intended use. — FDA requests for more data typically introduce regulatory uncertainty and potential delays in time-to-market.
-0.50Medicare has expanded reimbursement guidelines for transplant rejection testing, increasing covered surveillance tests from eight to 14. — Increased reimbursement frequency expands the addressable market and strengthens the economic incentive for adoption.
+0.40The company's projected cash burn for the second half of the year has increased to $8 million per quarter from a previous forecast of $6 million. — Higher-than-expected cash burn reduces the company's runway and increases the risk of future dilutive financing.
-0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Oncocyte continues to target FDA marketing authorization for GraftAssureDx later this year. — Maintaining the target timeline suggests management believes the FDA requests are routine and addressable.
+0.20The company plans to complete its European regulatory submission during the second half of the year, noting a more flexible process than the FDA. — Diversifying regulatory paths reduces reliance on a single market and provides an alternative route to revenue.
+0.20Which stocks this story touches
Positive tailwinds from expanded Medicare reimbursement and strong transplant center interest, offset by an FDA request for additional data and increased cash burn.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
3h ago
